Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutierrez F, Lopez Bernaldo de Quiros JC, Losa JE, Miro JM, Moreno S, Perez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Cayla J, Domingo P, Estrada V, Knobel H, Locutura J, Lopez Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Munoz A, Ocampo A, Olalla J, Perez I, Perez Elias MJ, Perez Arellano JL, Portilla J, Ribera E, Rodriguez F, Santin M, Sanz Sanz J, Tellez MJ, Torralba M, Valencia E, Von Wichmann MA.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11.

Despite the huge advance that antiretroviral therapy represents for the prognosis of infection by the human immunodeficiency virus (HIV), opportunistic infections (OIs) continue to be a cause of morbidity and mortality in HIV-infected patients. OIs often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an OI. The present article updates our previous guidelines on the prevention and treatment of various OIs in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome.

PMID: 26976381

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.